Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $62000.0.

  • Aytu Biopharma's Income towards Parent Company rose 10500.4% to $62000.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $116000.0, marking a year-over-year increase of 10869.57%. This contributed to the annual value of $620000.0 for FY2025, which is 11865.22% up from last year.
  • Per Aytu Biopharma's latest filing, its Income towards Parent Company stood at $62000.0 for Q2 2025, which was up 10500.4% from $54000.0 recorded in Q1 2025.
  • Aytu Biopharma's Income towards Parent Company's 5-year high stood at $381000.0 during Q3 2024, with a 5-year trough of -$53.3 million in Q1 2022.
  • In the last 5 years, Aytu Biopharma's Income towards Parent Company had a median value of -$1.9 million in 2023 and averaged -$9.6 million.
  • Per our database at Business Quant, Aytu Biopharma's Income towards Parent Company tumbled by 54679.52% in 2021 and then skyrocketed by 15888.72% in 2024.
  • Aytu Biopharma's Income towards Parent Company (Quarter) stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then soared by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
  • Its Income towards Parent Company stands at $62000.0 for Q2 2025, versus $54000.0 for Q1 2025 and $123000.0 for Q4 2024.